RxDoctor Payments Data

Shelly Lee, MD

Ophthalmology · Spokane, WANPI 1285817288

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,588 of the $3,801 with a category attached, or 68.1%. 15 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 34.9% of the total. Reporting peaked in 2019 at $1,976 and has fallen 79.8% since, to $400 in 2025.

$3,801in general payments, 2019–2025

Across 55 payments — averaging $69.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$1K
  • Alcon$678
  • US Retina LLC$479
  • Novartis$246
  • Astellas Pharma US Inc$217
  • AbbVie$209
  • plus $645 from 9 others
$23,469in research payments, 2019–2025

Across 5 payments — averaging $4693.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$8K
  • Mallinckrodt Hospital Products Inc.$6K
  • Mallinckrodt Enterprises LLC$6K
  • Eyepoint US, Inc.$4K

What the payments were for

  • Travel & lodging$73419%
  • Food & beverage$2,58868%
  • Ownership interest$47913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,801 in reported general payments places this provider in the 80th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$2,777,212
Medicare patients
417
Services billed
154,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate150$7,387
Mycophenolate Mofetil37$3,541
Difluprednate14$2,636
Atropine Sulfate69$2,259
Ketorolac Tromethamine32$1,732
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$908
Ofloxacin66$730
MethotrexateMethotrexate Sodium15$646
Brimonidine Tartrate82$499
Timolol Maleate25$465
Latanoprost54$456
ValacyclovirValacyclovir Hcl13$127
Prednisone22$80

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →